

# Quanterix

## Quanterix Names Frontage Laboratories as a Preferred Partner in Biomarker Assay Development and Testing Services in the Regulated Space

*In response to growing customer demand, Frontage Laboratories will leverage Quanterix's Simoa technology to provide enhanced sensitivity for assay development across a broad range of therapeutic areas*

**Lexington, Mass. – February 10, 2016** — [Quanterix Corporation](#), a leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced an alliance with Frontage Laboratories, naming the Company as a Preferred Partner for assay research and development. Leveraging Simoa's sensitivity and revolutionary digital approach for assay development and research, Frontage will have the ability to enter new markets and strengthen its current offerings.

Frontage is a full-service CRO assisting biopharmaceutical organizations in their research and product development efforts. Using Simoa's single molecule detection capabilities, Frontage will be able to provide their customers with a completely automated experience, ensuring consistent results and the greatest sensitivity possible.

"Frontage Laboratories' alliance with Quanterix is a natural fit for our companies. Incorporating Simoa's ultrasensitive single molecule measurement into our pipeline of assay development and services capabilities allows us to enter new markets and significantly strengthen current offerings, including LC-MS and LBA platforms," said Dr. John Lin, Senior Vice President, Bioanalytical and Biologics Services, Frontage Laboratories. "These capabilities are well complemented by Quanterix's Single Molecule Array technology to provide answers to problems in disease biology where basal levels of biomarker analytes have been extremely difficult to quantify. We anticipate our collaboration with Quanterix will bring unique content onto the platform and deliver high-sensitivity assay development."

"We couldn't be happier to add Frontage Laboratories to our preferred partner program," said Kevin Hrusovsky, CEO and Executive Chairman at Quanterix. "By combining their deep-rooted expertise in solving difficult assay development and protein quantification problems with the service offerings available in our own Simoa HD-1 Accelerator Lab, we're confident that this partnership will accelerate assay development and lead to groundbreaking discoveries in diverse therapeutic areas of research."

To learn more about Simoa, please visit: [www.quanterix.com](http://www.quanterix.com).

### **About Frontage Laboratories**

Founded in 2002, Frontage's business has grown to state-of-the art research facilities in the US and China. Spanning from the discovery stages through late-stage clinical trials, our full service offerings include bioanalysis, preclinical and clinical studies, analytical testing, product development support, DMPK and biometrics. Our company also provides turnkey product development, bioequivalence and analytical services to generic and consumer health pharmaceutical companies to support ANDA, and 505(b)(2) new drug application submissions. For more information, visit [www.frontagelab.com](http://www.frontagelab.com)

### **About Quanterix**

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing

applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: [www.quanterix.com](http://www.quanterix.com). Investors can access a webcast of Kevin Hrusovsky's recent JPMorgan presentation at: <http://info.quanterix.com/watch-quanterix-jp-morgan-healthcare-presentation>.

###

**Contacts:**

Caitlyn Keating

PAN Communications

617-502-4300

[quanterix@pancomm.com](mailto:quanterix@pancomm.com)